GeneDx Holdings Corp.
NASDAQ:WGSMedical - Healthcare Information Services
+$1.52 today
- Market cap
- $1.56B
- Beta
- 1.97
- P/E (TTM)
- -21.8
- EPS (TTM)
- -$2.65
Volume 1.71M
Average 1.28M
WGS Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
GeneDx Holdings Corp.NASDAQ: WGS
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $6.71M rose 8.4% year over year, behind the +15.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.4% from the prior quarter. Over 3 fiscal years it compounded at -24.8% a year.
Context
- Depreciation & amortization amounted to 5.9% of revenue in FY2025, down 1.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +8.4% toward the trailing-twelve-month pace of +15.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 25.22M USD
- Year-over-year change
- +14.9%
- 4-year CAGR
- +3.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.22M | +14.9% |
| FY2024 | 2024-12-31 | 21.95M | -34.9% |
| FY2023 | 2023-12-31 | 33.73M | -43.1% |
| FY2022 | 2022-12-31 | 59.31M | +172.0% |
| FY2021 | 2021-12-31 | 21.81M | — |
Depreciation & Amortization vs competitors
How WGS compares with its peers on the latest reported figures
- WGS's LTM Jun 2026 depreciation & amortization of $26.88M is the 3rd highest of the 9 companies compared; the peer median is $14.52M.
- Its year-over-year change of +15.1% is the 2nd highest of 9, against a peer median of -4.0%.
- Depreciation & amortization amounts to 5.9% of revenue for WGS, versus a peer median of 8.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $65.46M | -8.0% | -0.8% | 8.5% | |
| LTM Mar 2026 | $51.8M | -13.5% | +0.6% | 6.2% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $26.88M | +15.1% | -24.8% | 5.9% |
| LTM Mar 2026 | $24.2M | +0.1% | -9.6% | 7.6% | |
| LTM Mar 2026 | $16.75M | -60.5% | +57.0% | 4.9% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $12.3M | +13.9% | — | 3.1% |
| LTM Mar 2026 | $9.83M | -8.1% | +6.0% | 15.2% | |
| FY2025 | $9.21M | +14.5% | +23.3% | 8.5% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.34M | +35.9% | -25.1% | 119.9% |
| Peer median (excluding WGS) | $14.52M | -4.0% | +0.6% | 8.0% | |
Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 212.2M | 234.69M | 202.57M | 305.45M | 427.54M |
| Cost of Revenue | 228.8M | 261.44M | 112.56M | 111.05M | 129.37M |
| Gross Profit | (16.6M) | (26.75M) | 90.01M | 194.4M | 298.17M |
| Gross Margin | -7.8% | -11.4% | 44.4% | 63.6% | 69.7% |
| Research & Development | 105.16M | 86.2M | 58.27M | 45.72M | 72.03M |
| Selling, General & Admin | 318.73M | 338.24M | 194.71M | 168.48M | 239.22M |
| Operating Expenses | 429.55M | 640.9M | 270.6M | 217.61M | 311.25M |
| Depreciation & Amortization | 21.81M | 59.31M | 33.73M | 21.95M | 25.22M |
| EBITDA | (220.75M) | (398.2M) | (136.46M) | (27.64M) | 6.63M |
| EBITDA Margin | -104.0% | -169.7% | -67.4% | -9.1% | 1.5% |
| Operating Income | (446.15M) | (667.65M) | (180.6M) | (23.21M) | (11.8M) |
| Operating Margin | -210.3% | -284.5% | -89.2% | -7.6% | -2.8% |
| Interest Income | 79K | 2.54M | 1.11M | 0 | 0 |
| Interest Expense | 2.84M | 3.21M | 0 | 3.03M | 2.54M |
| Other Income / Expenses | 200.76M | 69.62M | 3.9M | (29.42M) | (9.34M) |
| Income Before Tax | (245.39M) | (598.03M) | (176.69M) | (52.63M) | (21.14M) |
| Pre-Tax Margin | -115.6% | -254.8% | -87.2% | -17.2% | -4.9% |
| Income Tax Expense | 0 | (49.05M) | (926K) | (343K) | (116K) |
| Net Income | (245.39M) | (548.98M) | (175.77M) | (52.29M) | (21.02M) |
| Net Margin | -115.6% | -233.9% | -86.8% | -17.1% | -4.9% |
| EPS (Basic) | (74.93) | (53.63) | (7.23) | (1.94) | (0.73) |
| EPS (Diluted) | (74.93) | (53.63) | (7.23) | (1.94) | (0.73) |
| Weighted Avg Shares | 3.28M | 10.24M | 24.31M | 26.89M | 26.89M |
| Weighted Avg Shares (Diluted) | 3.28M | 10.24M | 24.31M | 26.89M | 26.89M |
GeneDx Holdings Corp.
NASDAQ:WGS
Intrinsic Alpha fair value
Locked
Current Price
$51.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.